Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30747701 | 0.87 | LMNA (0.59) | ALDH1A1KDM4ELMNA | |
| SCHEMBL7545236 | 0.87 | LMNA (0.59) | ALDH1A1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL27329066 | 0.86 | LMNA (0.57) | ALDH1A1KDM4ELMNA | |
| Oxalic Acid SCHEMBL27853164 | 0.83 | LMNA (0.55) | ALDH1A1KDM4ELMNA | |
| SCHEMBL27324947 | 0.83 | LMNA (0.55) | ALDH1A1KDM4ELMNA | |
| Acetic Acid SCHEMBL27339243 | 0.83 | LMNA (0.55) | ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL784673 | 0.83 | KDM4E (0.44) | ALDH1A1KDM4EPOLBLMNAFABP4 | |
| Sulfuric Acid SCHEMBL27334527 | 0.82 | CHRM1 (0.56) | AKR1C3AKR1C1KDM4ELMNAFABP3 | |
| Toluene SCHEMBL27351014 | 0.81 | LMNA (0.52) | ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL22810540 | 0.80 | CREBBP (0.51) | ALDH1A1KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193741-A | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS INC | 2014-12-10 | — | — | CN | claimed |
| CN-103402996-A | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2013-11-20 | — | — | CN | claimed |
| CN-105593211-A | Indol and indazol derivatives | HOFFMANN LA ROCHE | 2016-05-18 | — | — | CN | disclosed |
| CN-102757422-B | The derivative of N-[(1H-pyrazol-1-yl) aryl]-1H-indoles or 1H-indazole-3-methane amide, its preparation method and application in the treatment thereof | SAI NUOFEI (FR) | 2015-09-16 | — | — | CN | disclosed |
| CN-104193741-A | QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | COMENTIS INC | 2014-12-10 | — | — | CN | disclosed |
| CN-103347874-B | dimeric IAP inhibitors | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | disclosed |
| CN-103619834-A | Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H-indazole-3-carboxamide, their preparation and their use as P2Y12 antagonists | SANOFI SA | 2014-03-05 | — | — | CN | disclosed |
| CN-101835779-B | Purine derivatives useful as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2014-01-29 | — | — | CN | disclosed |
| CN-103402996-A | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | AKR1C3 2302/4885AKR1C1 3346/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.